Tue, Mar 3, 2015, 3:27 AM EST - U.S. Markets open in 6 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell Oct 17, 2013 3:44 PM Flag

    BioCentury Featured 48 Leading Biopharma Companies (Exelixis is 1)

    REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - Sep 26, 2013) - BioCentury convened the 20th Annual NewsMakers in the Biotech Industry in New York City Friday, September 27, at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

    The event showcased 48 publicly traded biopharma companies independently selected on the basis of key clinical, regulatory and commercial milestones that will drive valuations going into 2014.
    The 2013 NewsMakers Presenting Companies

    The presenting companies represented an independently selected mix of biotechs with near-term commercial, regulatory and clinical milestones. They were screened using BioCentury's industry analysis and BCIQ online business intelligence platform.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don't know what happened to my post? Here it is again.The 2013 NewsMakers are outpacing the biotech bull market. The aggregate market cap of the NewsMakers companies has jumped this year from $23.6 billion to $39.8 billion through August. This is a 69% increase, compared with a 48% gain in the BioCentury 100 Index and a 53% gain in the NASDAQ Biotechnology Index (NBI). Investors also have poured more than $4.7 billion into the Class of 2013 since the beginning of 2012, including nearly $2.5 billion this year.

      "Biotech is in the midst of a record 5 year run, outpacing the key equity indices, including the Dow Jones Industrials, the S&P 500 and the NASDAQ Biotechnology Index," said BioCentury Publisher Eric Pierce. "Members of the NewsMakers Class of 2013 have played a significant role in drawing investors into the biotech space. We're pleased to have the opportunity to showcase them and their upcoming, near-term milestones to the investment community at NewsMakers."

      The NewsMakers pipeline is robust with both partnered and unpartnered programs that should be of interest to pharma business development and licensing professionals. The group has more than 50 products on the market, and nine compounds under regulatory review, including three with near-term PDUFA dates. The group is conducting more than 250 clinical trials, including 35 Phase III trials and more than 140 Phase II trials across key disease areas including cancer, infectious diseases, inflammation, cardiovascular and autoimmune disorders. The NewsMakers assets include more than 225 unpartnered programs, with more than 140 of them in the clinic and 70 in preclinical/IND stage

    • One of the 48, or rank #1 among the 48?

    • I'm not familiar with BioCentury but I wonder how the #1 companies for 2011 and 2012 have performed...

      • 1 Reply to roger5147
      • One of 48 companies.Which is pretty good considering there are thousands of BioTechs.BioCentury is from Houston;a PBS program.With some of the industries most intellectual minds having discussions with a very informed and intelligent host.I haven't looked for a transcript from the 20th Annual NewsMakers in the Biotech Industry in New York City Friday, September 27.If someone reads it and cares to make comments I'd appreciate it.Thanks.

 
EXEL
3.09+0.1600(+5.46%)Mar 2 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.